Ulcerative Colitis Treatment Market 2034: FDA Approvals, Clinical trials, Therapies, Prevalence and Companies by DelveInsight | Vedanta Biosciences, Palatin Technologies, Eli Lilly, Genentech, Pfizer, Amgen

(Albany, USA) DelveInsight's "Ulcerative Colitis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Ulcerative Colitis, historical and forecasted epidemiology as well as the Ulcerative Colitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Ulcerative Colitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Ulcerative Colitis Market Forecast https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key facts of the Ulcerative Colitis Market Report:
• The Ulcerative Colitis market size was valued approximately USD 8,400 Million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In April 2023, Merck & Co., Inc. has entered into an agreement to purchase Prometheus Biosciences at a cash price of USD 200.00 per share, totalling an approximate equity value of USD 10.8 billion. This acquisition provides an opportunity for Prometheus Biosciences to optimize the prospects of PRA023, an advanced candidate in the late stages of development intended for the treatment of ulcerative colitis, Crohn's disease, and various other autoimmune conditions.
• In December 2023, Insilico Medicine, headquartered in Hong Kong, initiated a Phase I clinical trial for ISM5411, a drug discovered using artificial intelligence (AI). This trial, registered under NCT06012578, aims to assess the safety, tolerability, pharmacokinetics, and food effects of ISM5411 in healthy volunteers. Approximately 76 participants are expected to be enrolled across Australia, with the trial outcomes anticipated by the conclusion of 2024.
• In November 2023, Landos Biopharma has released findings from the Phase Ib NEXUS study examining NX-13's effects on individuals with ulcerative colitis (UC). Most participants experienced prompt and uniform symptom relief, including reduced rectal bleeding and stool frequency, along with enhanced endoscopic outcomes within four weeks of treatment. Additionally, NX-13 demonstrated favorable tolerability across all subjects.
• In March 2023, Takeda Pharmaceutical Company Limited obtained approval from the Japanese Ministry of Health, Labour, and Welfare for its Entyvio Pens (vedolizumab) as a maintenance therapy for individuals with moderate to severe ulcerative colitis.
• In 2022, the overall number of individuals with ulcerative colitis (UC) in the seven major markets (7MM) was approximately 2,223,000. It is anticipated that these cases will increase by 2034, within the projected timeframe of 2023 to 2034.
• Within the seven major markets (7MM), the United States documented the highest number of prevalent cases of ulcerative colitis (UC) in 2022, totaling around 1,026,000. This figure constituted nearly 46% of the total cases reported across the 7MM during the same year.
• In the European Union Four (EU4) and the United Kingdom, Germany had the largest number of ulcerative colitis (UC) cases in 2022, amounting to approximately 357,000 cases.
• In 2022, the collective number of confirmed cases of ulcerative colitis (UC) in the seven major markets (7MM) was approximately 1,615,100.
• Within the European Union Four (EU4) and the United Kingdom in 2022, the overall number of existing cases of ulcerative colitis (UC) was around 1,024,000, with approximately 740,000 confirmed prevalent cases.
• Key Ulcerative Colitis Companies: Vedanta Biosciences, Inc., Palatin Technologies, Inc, Eli Lilly and Company, Genentech, Inc., Pfizer, Amgen, AbbVie, Landos Biopharma Inc., Ferring Pharmaceuticals, Mesoblast, Inc., Bristol-Myers Squibb, Oppilan Pharma Ltd, EA Pharma Co., Ltd., and others
• Key Ulcerative Colitis Therapies: VE202, PL8177 Placebo, Mirikizumab, Vixarelimab, Etrasimod, Efavaleukin alfa, ABBV-668, NX-13, 5-ASA, Remestemcel-L, Ozanimod, VTX002, AJM300, and others
• The Ulcerative Colitis epidemiology based on severity-based cases analyzed that moderate-to-severe UC cases accounts for ~55% of the total cases and the rest of the cases falls under mild category.
• The Ulcerative Colitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Ulcerative Colitis pipeline products will significantly revolutionize the Ulcerative Colitis market dynamics.

Ulcerative Colitis Overview
Ulcerative colitis is a chronic inflammatory bowel disease (IBD) characterized by inflammation and ulcers in the colon and rectm. It is one of the two main types of IBD, the other being Crohn's disease. Ulcerative colitis specifically affects the innermost lining of the large intestine (colon) and the rectm.

Get a Free sample for the Ulcerative Colitis Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Ulcerative Colitis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Ulcerative Colitis Epidemiology Segmentation:
The Ulcerative Colitis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Ulcerative Colitis
• Prevalent Cases of Ulcerative Colitis by severity
• Gender-specific Prevalence of Ulcerative Colitis
• Diagnosed Cases of Episodic and Chronic Ulcerative Colitis

Download the report to understand which factors are driving Ulcerative Colitis epidemiology trends @ Ulcerative Colitis Epidemiology Forecast
https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Ulcerative Colitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ulcerative Colitis market or expected to get launched during the study period. The analysis covers Ulcerative Colitis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Ulcerative Colitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Ulcerative Colitis Therapies and Key Companies
• VE202: Vedanta Biosciences, Inc.
• PL8177 Placebo: Palatin Technologies, Inc
• Mirikizumab: Eli Lilly and Company
• Vixarelimab: Genentech, Inc.
• Etrasimod: Pfizer
• Efavaleukin alfa: Amgen
• ABBV-668: AbbVie
• NX-13: Landos Biopharma Inc.
• 5-ASA: Ferring Pharmaceuticals
• Remestemcel-L: Mesoblast, Inc.
• Ozanimod: Bristol-Myers Squibb
• VTX002: Oppilan Pharma Ltd
• AJM300: EA Pharma Co., Ltd.

Discover more about therapies set to grab major Ulcerative Colitis market share @ Ulcerative Colitis Treatment Landscape
https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Ulcerative Colitis Market Strengths
• With the market dynamics shifting towards medications with oral ROA, emergence of therapies like, BT-11, AJM300, Etrasimod, and SHR0302 will further drive the UC therapeutic market.
• Robust emerging pipeline with novel MOAs with less immunogenicity such as cobitolimod, BBT-401, Omilancor, and others are likely to strengthen the market.

Ulcerative Colitis Market Opportunities
• There lies tremendous potential in the UC landscape for drugs with better clinical profile especially in terms of safety. Safety concerns associated with JAK inhibitors poses a great opportunity for pharmaceutical companies to work on this front and improve the safety profile ofupcoming drugs.
• Limited treatment options available in case of relapsed or refractory pool, provides lucrative opportunities in the UC therapeutic space.

Scope of the Ulcerative Colitis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Ulcerative Colitis Companies: Vedanta Biosciences, Inc., Palatin Technologies, Inc, Eli Lilly and Company, Genentech, Inc., Pfizer, Amgen, AbbVie, Landos Biopharma Inc., Ferring Pharmaceuticals, Mesoblast, Inc., Bristol-Myers Squibb, Oppilan Pharma Ltd, EA Pharma Co., Ltd., and others
• Key Ulcerative Colitis Therapies: VE202, PL8177 Placebo, Mirikizumab, Vixarelimab, Etrasimod, Efavaleukin alfa, ABBV-668, NX-13, 5-ASA, Remestemcel-L, Ozanimod, VTX002, AJM300, and others
• Ulcerative Colitis Therapeutic Assessment: Ulcerative Colitis current marketed and Ulcerative Colitis emerging therapies
• Ulcerative Colitis Market Dynamics: Ulcerative Colitis market drivers and Ulcerative Colitis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Ulcerative Colitis Unmet Needs, KOL's views, Analyst's views, Ulcerative Colitis Market Access and Reimbursement

To know more about Ulcerative Colitis companies working in the treatment market, visit @ Ulcerative Colitis Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Ulcerative Colitis Market Report Introduction
2. Executive Summary for Ulcerative Colitis
3. SWOT analysis of Ulcerative Colitis
4. Ulcerative Colitis Patient Share (%) Overview at a Glance
5. Ulcerative Colitis Market Overview at a Glance
6. Ulcerative Colitis Disease Background and Overview
7. Ulcerative Colitis Epidemiology and Patient Population
8. Country-Specific Patient Population of Ulcerative Colitis
9. Ulcerative Colitis Current Treatment and Medical Practices
10. Ulcerative Colitis Unmet Needs
11. Ulcerative Colitis Emerging Therapies
12. Ulcerative Colitis Market Outlook
13. Country-Wise Ulcerative Colitis Market Analysis (2020-2034)
14. Ulcerative Colitis Market Access and Reimbursement of Therapies
15. Ulcerative Colitis Market Drivers
16. Ulcerative Colitis Market Barriers
17. Ulcerative Colitis Appendix
18. Ulcerative Colitis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Trending Reports:
• Hepatic Encephalopathy Epidemiology Forecast: https://www.delveinsight.com/report-store/hepatic-encephalopathy-epidemiology-forecast
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/anti-cd274-pd-l1-antibody-pipeline-insight
• Anti-gbm Market: https://www.delveinsight.com/report-store/anti-glomerular-basement-membrane-anti-gbm-disease-market-insights
• Autosomal Recessive Congenital Ichthyosis Market Size: https://www.delveinsight.com/report-store/autosomal-recessive-congenital-ichthyosis-market
• Cholangiocarcinoma Market: https://www.delveinsight.com/report-store/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast
• Chronic Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Egfr Non-small Cell Lung Cancer Market: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-market
• Familial Chylomicronemia Syndrome Market: https://www.delveinsight.com/report-store/familial-chylomicronemia-syndrome-market
• Lhon Market: https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market
• Ocular Motility Disturbance Market: https://www.delveinsight.com/report-store/ocular-motility-disturbance-market
• Rituximab Biosimilars Insight: https://www.delveinsight.com/report-store/rituximab-biosimilars-insight
• Severe Hypertriglyceridemia Market: https://www.delveinsight.com/report-store/severe-hypertriglyceridemia-shtg-market
• Waiha Market: https://www.delveinsight.com/report-store/warm-autoimmune-hemolytic-anemia-waiha-market
• Acute On Chronic Liver Failure Aclf Market: https://www.delveinsight.com/infographics/acute-on-chronic-liver-failure-aclf-market
• Adult Onset Still Disease Market: https://www.delveinsight.com/blog/adult-onset-stills-disease-treatment-market
• Alport Syndrome Market: https://www.delveinsight.com/report-store/alport-syndrome-market
• Chronic Inducible Urticaria Market: https://www.delveinsight.com/report-store/chronic-spontaneous-urticaria-market
• Diffuse Large B-cell Lymphoma Market: https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-market
• Heavy Metal Poisoning Market: https://www.delveinsight.com/report-store/heavy-metal-poisoning-market
• Multiple Myeloma Market: https://www.delveinsight.com/report-store/multiple-myeloma-market
• Prosthetic Joint Infection Market: https://www.delveinsight.com/report-store/prosthetic-joint-infection-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/asco-conference-coverage

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.